BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Olmesartan Medoxomil

An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.

300+ PubMed studies analyzed · 61 RCTs · Evidence Score: 54.4

Research Domains

Olmesartan Medoxomil has been studied across 15 research domains including ❤️ Cardiovascular, 🔥 Metabolic, 🦴 Bone & Joint, 🫁 Liver & Detox, 🫘 Kidney. The primary research focus is ❤️ Cardiovascular with 57% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Olmesartan Medoxomil, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Abacavir
4 shared targets
Lamivudine
4 shared targets
Rifamycins
4 shared targets
Rifamycins
4 shared targets
beta
3 shared targets
Fusidic
2 shared targets
Irbesartan
5 shared targets
Valsartan
3 shared targets
Losartan
6 shared targets
Taurocholic
3 shared targets
Loading evidence profile...

This evidence profile for Olmesartan Medoxomil is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.